Author:
Wray Sibyl,Then Bergh Florian,Wundes Annette,Arnold Douglas L.,Drulovic Jelena,Jasinska Elzbieta,Bowen James D.,Negroski Donald,Naismith Robert T.,Hunter Samuel F.,Gudesblatt Mark,Chen Hailu,Lyons Jennifer,Shankar Sai L.,Kapadia Shivani,Mendoza Jason P.,Singer Barry A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference38 articles.
1. Disease-modifying therapies for MS. 2021. https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-The-MS-Disease-Modifying-Medications.pdf. Accessed May 11, 2021.
2. Fox RJ, Salter AR, Tyry T, et al. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the North American Research Committee on Multiple Sclerosis database. Int J MS Care. 2013;15(4):194–201.
3. Copaxone (glatiramer acetate) Prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020622s102lbl.pdf. Accessed Feb 22, 2021.
4. Rebif (interferon beta-1a) Prescribing Information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103780s5178s5179lbl.pdf. Accessed Feb 22, 2021.
5. Avonex (interferon beta-1a) Prescribing Information. 2020. https://www.avonex.com/content/dam/commercial/avonex/pat/en_us/pdf/Avonex_US_Prescribing_Information.pdf. Accessed Feb 22, 2021.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献